{
    "name": "ceftaroline",
    "comment": "Rx",
    "other_names": [
        "Teflaro"
    ],
    "classes": [
        "Cephalosporins",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/teflaro-ceftaroline-999606",
    "pregnancy": {
        "common": [
            "No data in pregnant women are available"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In developmental toxicity studies conducted in animals, no malformations or other adverse developmental effects were observed in offspring of rats exposed at up to 4 times the maximum recommended human dose (MRHD) during the period of organogenesis through lactation",
                    "In rabbits exposed to ceftaroline during organogenesis at levels approximately equal to the MRHD, no drug-induced fetal malformations were observed despite maternal toxicity"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data are available regarding presence in human milk, or the effects on breastfed infants or on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug, excipients or other cephalosporins"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "If anemia develops during or after treatment, consider drug-induced hemolytic anemia; perform diagnostic studies including a direct Coombsâ€™ test; if drug-induced hemolytic anemia suspected, consider discontinuation; administer supportive care to patient (i.e. transfusion) if clinically indicated",
                "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
                "Neurological adverse reactions reported during postmarketing surveillance in patients treated with cephalosporins; reactions include encephalopathy and seizures; most cases occurred in patients with renal impairment who did not receive appropriate dosage adjustment; if neurological adverse reactions occur, consider discontinuing therapy or making appropriate dosage adjustments in patients with renal impairment"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions reported in patients receiving beta-lactam antibacterial drugs",
                        "Before therapy is instituted, make careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or carbapenems",
                        "Maintain clinical supervision if product is to be given to a penicillin-or other beta-lactam-allergic patient; cross sensitivity among beta-lactam antibacterial agents has been clearly established; if allergic reaction occurs, discontinue therapy and institute appropriate treatment and supportive measures"
                    ]
                },
                {
                    "type": "Clostridium difficile-associated diarrhea (CDAD)",
                    "description": [
                        "CDAD reported for nearly all systemic antibacterial agents and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon and may permit overgrowth of C. difficile",
                        "C. difficile ",
                        "produces toxins A and B which contribute to development of CDAD; hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy",
                        "CDAD must be considered in all patients who present with diarrhea following antibiotic use; careful medical history is necessary because CDAD has been reported to occur more than 2 months after administration of antibacterial agents",
                        "If CDAD is suspected or confirmed, antibacterials not directed against ",
                        "C. ",
                        "difficile should be discontinued, if possible; institute appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation as clinically indicated"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "BCG intravesical live",
            "description": {
                "common": "ceftaroline decreases effects of BCG intravesical live by pharmacodynamic antagonism. Contraindicated. Contraindicated; wait until antibiotic treatment completed."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "ceftaroline decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Delay vaccine until 3 days after antibiotic course completed, or administer 3 days before antibiotic initiated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "ceftaroline, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "microbiota oral",
            "description": {
                "common": "ceftaroline decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and ceftaroline both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "probenecid increases levels of ceftaroline by acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "ceftaroline decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "ceftaroline increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alteplase",
            "description": {
                "common": "ceftaroline increases effects of alteplase by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "ceftaroline increases effects of antithrombin III by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "argatroban",
            "description": {
                "common": "ceftaroline increases effects of argatroban by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "ceftaroline increases effects of bivalirudin by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dalteparin",
            "description": {
                "common": "ceftaroline increases effects of dalteparin by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "ceftaroline increases effects of enoxaparin by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "ceftaroline increases effects of fondaparinux by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "heparin",
            "description": {
                "common": "ceftaroline increases effects of heparin by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentosan polysulfate sodium",
            "description": {
                "common": "ceftaroline increases effects of pentosan polysulfate sodium by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "reteplase",
            "description": {
                "common": "ceftaroline increases effects of reteplase by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tenecteplase",
            "description": {
                "common": "ceftaroline increases effects of tenecteplase by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "eosinophilia",
            "percent": null
        },
        {
            "name": "neutropenia",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "palpitations",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "anaphylaxis",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Clostridium difficile colitis",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Hyperglycemia",
            "percent": null
        },
        {
            "name": "hyperkalemia",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "convulsion",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Renal failure",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        }
    ]
}